trending Market Intelligence /marketintelligence/en/news-insights/trending/py3khab5-sob6laq5juxva2 content esgSubNav
In This List

Indivior secures license for C4X Discovery's therapies for substance addiction

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Indivior secures license for C4X Discovery's therapies for substance addiction

Indivior PLC agreed to buy exclusive global rights to develop and commercialize U.K.-based C4X Discovery Holdings PLC's potential treatment for substance addiction.

Under the agreement, the Richmond, Va.-based Indivior would pay C4X $10 million upfront, with potential milestone payments of up to $284 million.

The deal involves C4X Discovery's drugs, including lead candidate C4X3256, that block the orexin-1 protein in the body to decrease addiction related to opioids, alcohol and psychomotor stimulants such as cocaine.